ArticlePediatric blood & cancer2025

Standard-Dose Versus High-Dose Cisplatin for Intermediate/Poor-Risk Extracranial Malignant Germ Cell Tumors: Re-Analysis of Pediatric Oncology Group 9049 and Children's Cancer Group 8882 Trial Using Updated MaGIC Risk Stratification.

Daniel Prior et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.